Venture capital investors in the healthtech sector are transitioning their focus from digital pharmacies towards niche startups specializing in areas such as AI diagnostics, stem cell therapy, and medical devices. While digital pharmacies like PharmEasy dominated the investment landscape in recent years, a significant shift is now observable towards startups like Innovaccer, Neuberg Diagnostics, and Qure.ai, catering to more specialized healthcare needs.
Innovaccer, a company offering AI-powered data analytics solutions for healthcare providers, raised a substantial $275 million in funding earlier this year. Neuberg Diagnostics, a diagnostic service provider operating across multiple countries, secured $109 million in investment. Qure.ai, utilizing AI for early detection in radiology exams, raised $65 million. The surge in investments towards specialized healthtech startups can be attributed to the potential for high value creation, especially for companies with strong intellectual property portfolios, and the possibility of being acquired by larger pharmaceutical firms in the future.
The declining interest in digital pharmacies is also influenced by regulatory uncertainties surrounding online medicine sales. Pending rules to regulate this sector, coupled with concerns raised by chemist associations, have led investors to shift their attention towards single specialty healthcare and healthcare AI startups addressing global markets, as stated by Nithin Kaimal from Bessemer Venture Partners India.
Among the prominent trends in healthtech investments, the incorporation of AI stands out as a common theme among early-stage investors. Startups leveraging AI for healthcare services and diagnostics are gaining significant traction, with a focus on enhancing patient care throughout the treatment process, from pre-operative to post-operative stages. Investors like Arise Ventures, Endiya Partners, and 3one4 Capital are actively seeking out companies utilizing AI in healthcare, recognizing the immense potential for innovation in this space.
Endiya Partners, specifically interested in startups targeting non-communicable diseases like diabetes and hypertension, has made strategic investments in companies working on stem cell and gene therapy. Eyestem and Nkure Therapeutics are two such examples, developing innovative approaches for treating incurable diseases and cancer, respectively. Despite the promising prospects in specialized healthtech startups, the sector faces several significant challenges, akin to those encountered by deeptech companies.
Monetizing direct-to-consumer healthtech poses a considerable challenge for Indian firms, with the real profit potential lying in catering directly to hospitals and offering specialized diagnostics covered under insurance. However, the low health insurance penetration rate in India, with 70% of the population still uncovered, presents a hurdle for healthtech startups offering services tied to hospitals and their patient pools. A robust payer mechanism is deemed essential for the scalability of pure healthtech startups, suggesting a hybrid business model integrating digital and physical services as a viable solution.
Navigating regulatory processes is another obstacle faced by healthtech startups, particularly in obtaining approvals from organizations like the Central Drugs Standard Control Organisation. The lengthy approval timelines can significantly impact product launches and scaling efforts for companies in the hardware and lifesciences-based sectors. Additionally, securing venture funding remains a challenge, with limited avenues available for healthcare startups to access capital, despite initiatives like grants from institutions such as the Department of Biotechnology’s Biotechnology Industry Research Assistance Council.
In conclusion, while the landscape of healthtech investments in India is evolving towards specialized startups leveraging AI and innovative therapies like stem cell and gene therapy, the sector grapples with challenges related to funding, regulatory hurdles, and the need for robust business models to ensure scalability and sustainability. Overcoming these obstacles will be pivotal in unlocking the full potential of healthtech innovation and driving meaningful advancements in healthcare delivery and patient outcomes.
Takeaways:
– Specialized healthtech startups focusing on AI, stem cell therapy, and medical devices are gaining increased investor attention in India.
– Challenges such as regulatory uncertainties, low health insurance penetration, and limited funding avenues pose significant hurdles for healthtech startups.
– Hybrid business models integrating digital and physical services are crucial for scaling pure healthtech startups in the Indian market.
– Leveraging AI for healthcare services and diagnostics presents substantial opportunities for innovation and improving patient care outcomes.
Tags: regulatory, cell therapy, cell therapies, scale up, gene therapy
Read more on livemint.com